Alnylam's ALN-HTT02 heads to H2 2026 safety readout in Huntington's
The Phase 1 trial tests tolerability of a huntingtin-lowering RNAi drug, with mHTT knockdown in spinal fluid as the biology to watch alongside adverse events.
Executive Summary
- Alnylam Pharmaceuticals is preparing to disclose the first human data on its huntingtin-lowering RNAi candidate for Huntington's disease, with a safety and biomarker readout guided for the second half of 2026.
- The trial is built to answer a tolerability question first: whether the drug and its placebo-controlled, open-label extension design produce an acceptable adverse-event profile, with target engagement in spinal fluid as a secondary signal.
- No other clinical-stage program combines this target and this delivery approach in Huntington's disease, placing the trial in a field where the nearest rivals use different modalities and mechanisms to reach the same protein.
- The trial has moved cleanly toward its enrollment target with no shortfall, and Alnylam has held its guidance window steady across three consecutive quarters, both signs that execution is not the open issue heading into the readout.
The trial
ALN-HTT02 is being tested in NCT06585449, a Phase 1 study enrolling adults with stage 2 or early stage 3 Huntington's disease across sites in the United Kingdom, Germany, and Canada. The trial is randomized against placebo, includes a double-blind part and an open-label extension, and targets 66 patients. Its three registered primary endpoints all measure the frequency of adverse events across the open-label, double-blind, and open-label-extension phases of the study, making this fundamentally a safety and tolerability trial rather than an efficacy trial. NCT06585449A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseNCT06585449
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The biomarker to watch
Beyond safety, the trial's secondary endpoints track concentrations of ALN-HTT02 in plasma, urine, and cerebrospinal fluid, and change from baseline in mutant huntingtin levels in cerebrospinal fluid. That CSF mutant-huntingtin measure is the pharmacodynamic signal that will show whether the drug is doing what an RNAi therapy targeting this gene is designed to do: silence the toxic protein at its source. A safety-clean readout paired with detectable knockdown would be the combination that matters most for how this program is read going into later-stage development. NCT06585449A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseNCT06585449
The guidance
Alnylam has repeated the same H2-2026 data-readout window in three separate disclosures dated January 11, February 12, and April 30, 2026, including its Alnylam 2030 strategy announcement. That consistency, unchanged across a full quarter of company reporting, is itself a signal of timing discipline rather than a slipping commitment. AlnylamAlnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient ImpactJan 11, 2026
Trial mechanics
The trial's primary completion date moved from December 15, 2027 to July 5, 2028 in November 2024, shortly after the study began recruiting, and its anticipated enrollment target rose from 54 to 66 patients in February 2026, a Phase 1 increase that the trial's own operational baseline treats as a routine, in-band change rather than a shortfall. The trial has been recruiting since November 2024 and remains active. NCT06585449A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseNCT06585449
The competitive field
No industry trial combines the mHTT target with an RNAi modality anywhere outside Alnylam's own program, and the nearest precedent for this specific target-modality pairing in Huntington's disease does not exist in the current competitive field. The nearest neighbors reach the huntingtin protein through different routes: Novartis's votoplam works through a splicing mechanism aimed at the huntingtin pre-mRNA transcript, and Hoffmann-La Roche's tominersen is an antisense oligonucleotide against HTT, both mechanistically distinct from Alnylam's siRNA approach. Roche's tominersen recorded a landscape risk score in the challenging range with five flagged operational signals, underscoring that the broader class of huntingtin-lowering approaches has not yet produced a clean precedent in this indication.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.